Kamada Ltd KMDA reported positive topline results from its Phase 2 biomarker study of inhaled alpha-1 [AAT-IH] for the treatment of alpha-1 antitrypsin deficiency [AATD]. H.C. Wainwright’s Andrew S. Fein maintained a Buy rating on the company, with a price target of $10.
The Phase 2 study of AAT-IH in AATD patients demonstrated “a significant increase in endothelial lining fluid (ELF) AAT antigenic level compared to the placebo group,” analyst Fein mentioned.
3 Objectives Met
Fein commented that although this was not a registrational study, the positive results achieve three important objectives for the long-run realization of value for AAT-IH.
- Objective 1: Fein commented that the first objective accomplished was gaining “incremental proof” that AAT has efficacy in inhalation formulation.
- Objective 2: Kamada is currently compiling responses to the EMA’s 120-day of questioning, and the Phase 2 results provide more data that can be submitted to the EMA.
- Objective 3: Kamada is also in ongoing discussions with the FDA and the Phase 2 readout is a step closer to “solidifying a registrational trial design with an approvable clinically meaningful endpoint,” which is expected to be another key catalyst for the company’s stock, the analyst stated.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.